 LA JOLLA, Calif.--BUSINESS WIRE--DermTech, Inc. NASDAQ: DMTK DermTech, a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that Geisinger Health System Geisinger has issued a positive medical benefit policy for its Commercial and Medicare Business Segment for the DermTech Pigmented Lesion Assay PLA. DermTechs PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99 negative predicti 